|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-4-14
|
|
pubmed:abstractText |
Intravenous recombinant human lymphotoxin-alpha derivative (rhLTalpha-Da) is a novel biological antitumor reagent developed in China. This study was to evaluate the tolerance of tumor patients to rhLTalpha-Da, confirm its maximum tolerable dose (MTD) in vivo, and to provide recommending dose for phase II trial.
|
|
pubmed:language |
chi
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1000-467X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
501-4
|
|
pubmed:meshHeading |
pubmed-meshheading:16613689-Adult,
pubmed-meshheading:16613689-Aged,
pubmed-meshheading:16613689-Chills,
pubmed-meshheading:16613689-Dose-Response Relationship, Drug,
pubmed-meshheading:16613689-Dyspnea,
pubmed-meshheading:16613689-Female,
pubmed-meshheading:16613689-Fever,
pubmed-meshheading:16613689-Humans,
pubmed-meshheading:16613689-Kidney Neoplasms,
pubmed-meshheading:16613689-Lymphotoxin-alpha,
pubmed-meshheading:16613689-Male,
pubmed-meshheading:16613689-Maximum Tolerated Dose,
pubmed-meshheading:16613689-Melanoma,
pubmed-meshheading:16613689-Middle Aged,
pubmed-meshheading:16613689-Nasopharyngeal Neoplasms,
pubmed-meshheading:16613689-Recombinant Proteins,
pubmed-meshheading:16613689-Young Adult
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
[Phase I clinical trial of intravenous recombinant human lymphotoxin-alpha derivative].
|
|
pubmed:affiliation |
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong 510060, P. R. China.
|
|
pubmed:publicationType |
Journal Article,
English Abstract,
Clinical Trial, Phase I
|
